Publications

GLUCOCORTICOID RECEPTOR (GR) ANTAGONIST PROGRAM: ORIC-101

ORIC publications

ORIC-101 overcomes GR-driven resistance to AR degradation in castration-resistant prostate cancer models
Poster presented at: 2020 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, October 24-25, 2020. Poster PD-050
ORIC-101 comprehensively inhibits glucocorticoid pathways to overcome therapeutic resistance in pan-cancer models
Poster presented at: 2020 American Association for Cancer Research; June 22-24, 2020. Poster #4120.
ORIC-101 overcomes resistance to diverse chemotherapeutics across cancer types
Poster presented at: 2020 American Association for Cancer Research; June 22-24, 2020. Poster #4121.
ORIC-101 overcomes glucocorticoid receptor-mediated chemoresistance in pancreatic cancer models
Poster presented at: 2020 American Association for Cancer Research; June 22-24, 2020. Poster #4123.
An open-label Phase 1b study of ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide
Poster presented at: 2020 Genitourinary Cancers Symposium; February 13–15, 2020; San Francisco, CA, USA. Abstract #TPS253.
ORIC-101 robustly inhibits the glucocorticoid pathway and overcomes chemoresistance in TNBC
Poster presented at: 2019 San Antonio Breast Cancer Symposium; December 14, 2019; San Antonio, TX, USA. Abstract #2507.
ORIC-101 overcomes glucocorticoid-driven resistance to androgen receptor inhibition in CRPC
Poster presented at: 2019 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; October 27, 2019; Boston, MA, USA. Abstract LB-A10.

CD73 INHIBITOR PROGRAM: ORIC-533

CD73 inhibition with a novel orally bioavailable small molecule blocks adenosine production and rescues T-cell activation
Poster presented at: 2020 American Association for Cancer Research; June 22-24, 2020. Poster #1023
An orally bioavailable inhibitor of CD73 reverts intratumoral immunosuppression and promotes anti-tumor response
Poster presented at: 2020 American Association for Cancer Research; June 22-24, 2020. Poster #LB-115
Orally available small molecule CD73 inhibitor reverses immunosuppression through blocking of adenosine production
Presented at: 2020 American Association for Cancer Research; April 27, 2020. Abstract #1242, presentation 1037.
Intratumoral immunosuppression is reversed by blocking adenosine production with an oral inhibitor of CD73
Poster presented at: 2019 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; October 27, 2019; Boston, MA, USA. Abstract LB-A19.